Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-06-27 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the recommendation for EU approval of Enhertu for breast cancer treatment, including clinical trial results, regulatory status, and company background. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document is not an annual report, earnings release, or management discussion, but rather a regulatory filing providing material updates. The length of the document (15,000 characters) and the detailed content confirm it is a substantive regulatory announcement rather than a brief notice or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-06-27 English
LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains a detailed announcement about Lynparza being recommended for approval in the EU for early breast cancer, including clinical trial results, drug information, and company background. The document is not a full annual or quarterly report, nor is it an earnings release or a regulatory certification. It is a regulatory filing that provides material information about the company's product development and regulatory status but does not contain comprehensive financial statements or management discussion of financial results. Form 6-K filings are typically classified under Regulatory Filings (RNS) as they serve as periodic reports for foreign issuers to disclose material information to the SEC and investors.
2022-06-27 English
Enhertu recommended for breast cancer EU approval
Regulatory Filings Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number : 2102Q) on June 27, 2022, detailing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the approval of Enhertu for HER2-positive metastatic breast cancer in the EU. This type of announcement, which communicates a specific regulatory or clinical development update, is characteristic of a general regulatory filing or news release. Since it is not a full annual report (10-K), an earnings release (ER), a quarterly report (IR), or a presentation (IP), and it is a specific, time-sensitive regulatory update, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements that don't fit elsewhere. The document length (15,932 chars) is substantial, suggesting it is the primary announcement itself, not just a brief notice of publication (RPA).
2022-06-27 English
Lynparza recommended in EU for early breast cancer
Regulatory Filings Classification · 98% confidence The document is a press release dated June 27, 2022, originating from AstraZeneca PLC, identified by the RNS Number (2099Q). It announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the recommendation for marketing authorisation of Lynparza in the EU for a specific cancer treatment. This type of announcement, detailing regulatory milestones, clinical trial results, and product updates, is characteristic of a general regulatory announcement or press release concerning company news, rather than a formal financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a formal announcement disseminated via the RNS system that doesn't fit the more specific categories (like ER, CT, or DIV), the most appropriate classification is the general Regulatory Filings category.
2022-06-27 English
Group of companies' accounts made up to 2021-12-31
Regulatory Filings
2022-06-24 English
EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about positive interim Phase III clinical trial results for the drug eplontersen, including endpoints met, safety profile, and plans for regulatory filing. The document is not an annual or quarterly report, nor is it a transcript, audit, or management change announcement. It is a regulatory filing providing material information about clinical trial results and future regulatory plans. The document length is 11,531 characters, indicating it is a substantive report rather than a brief announcement. The Form 6-K is a standard SEC filing for foreign issuers to report material information and is classified under Regulatory Filings (RNS) as it does not fit other specific categories like Annual Report or Earnings Release.
2022-06-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.